Display options
Cite
Noori M, Nejadghaderi SA, Arshi S, et al. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Rev Med Virol. 2021;e2277doi: 10.1002/rmv.2277.
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson-Chahhoud, K., Ansarin, K., Kolahi, A. A., & Safiri, S. (2021). Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Reviews in medical virology, e2277. https://doi.org/10.1002/rmv.2277
Noori, Maryam, et al. "Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies." Reviews in medical virology vol. (2021): e2277. doi: https://doi.org/10.1002/rmv.2277
Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, Safiri S. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Rev Med Virol. 2021 Jul 19;e2277. doi: 10.1002/rmv.2277. Epub 2021 Jul 19. PMID: 34286893; PMCID: PMC8420542.
Copy Download .nbib Format: NLM
Share it on

Rev Med Virol. 2021 Jul 19;e2277. doi: 10.1002/rmv.2277. Epub 2021 Jul 19.

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.

Reviews in medical virology

Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, Kristin Carson-Chahhoud, Khalil Ansarin, Ali-Asghar Kolahi, Saeid Safiri

Affiliations

  1. Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  2. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  4. Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  5. Australian Centre for Precision Health, Allied Health and Human Performance, University of South Australia, South Australia, Australia.
  6. School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
  7. Rahat Breath and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  8. Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  9. Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

PMID: 34286893 PMCID: PMC8420542 DOI: 10.1002/rmv.2277

Abstract

BNT162b2 and mRNA-1273 are two types of mRNA-based vaccine platforms that have received emergency use authorization. The emergence of novel severe acute respiratory syndrome (SARS-CoV-2) variants has raised concerns of reduced sensitivity to neutralization by their elicited antibodies. We aimed to systematically review the most recent in vitro studies evaluating the effectiveness of BNT162b2 and mRNA-1273 induced neutralizing antibodies against SARS-CoV-2 variants of concern. We searched PubMed, Scopus, and Web of Science in addition to bioRxiv and medRxiv with terms including 'SARS-CoV-2', 'BNT162b2', 'mRNA-1273', and 'neutralizing antibody' up to June 29, 2021. A modified version of the Consolidated Standards of Reporting Trials (CONSORT) checklist was used for assessing included study quality. A total 36 in vitro studies meeting the eligibility criteria were included in this systematic review. B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) are four SARS-CoV-2 variants that have recently been identified as variants of concern. Included studies implemented different methods regarding pseudovirus or live virus neutralization assays for measuring neutralization titres against utilized viruses. After two dose vaccination by BNT162b2 or mRNA-1273, the B.1.351 variant had the least sensitivity to neutralizing antibodies, while B.1.1.7 variant had the most sensitivity; that is, it was better neutralized relative to the comparator strain. P.1 and B.1.617.2 variants had an intermediate level of impaired naturalization activity of antibodies elicited by prior vaccination. Our review suggests that immune sera derived from vaccinated individuals might show reduced protection of individuals immunized with mRNA vaccines against more recent SARS-CoV-2 variants of concern.

© 2021 John Wiley & Sons Ltd.

Keywords: BNT162b2; SARS-CoV-2; mRNA-1273; neutralizing antibody; variants of concern

References

  1. Cell. 2021 May 27;184(11):2939-2954.e9 - PubMed
  2. N Engl J Med. 2021 Jun 17;384(24):2352-2354 - PubMed
  3. N Engl J Med. 2021 Mar 8;384(15):1466-1468 - PubMed
  4. Microorganisms. 2021 Jul 20;9(7): - PubMed
  5. Clin Infect Dis. 2021 Jun 16;: - PubMed
  6. Rev Med Virol. 2021 Mar;31(2):e2170 - PubMed
  7. Science. 2020 Aug 7;369(6504):643-650 - PubMed
  8. Elife. 2020 Oct 28;9: - PubMed
  9. Lancet. 2021 Jun 19;397(10292):2331-2333 - PubMed
  10. Cell. 2021 Apr 29;184(9):2372-2383.e9 - PubMed
  11. Cell. 2021 Jun 24;184(13):3426-3437.e8 - PubMed
  12. Science. 2021 Aug 6;373(6555):648-654 - PubMed
  13. Med Drug Discov. 2021 Jun;10:100086 - PubMed
  14. Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2 - PubMed
  15. Cell. 2021 Jan 7;184(1):64-75.e11 - PubMed
  16. J Exp Med. 2020 Nov 2;217(11): - PubMed
  17. Lancet Microbe. 2021 Jul;2(7):e283-e284 - PubMed
  18. N Engl J Med. 2021 Jul 8;385(2):187-189 - PubMed
  19. Nature. 2020 Oct;586(7830):567-571 - PubMed
  20. Nature. 2020 Oct;586(7830):594-599 - PubMed
  21. Cell. 2021 Apr 29;184(9):2384-2393.e12 - PubMed
  22. J Infect Dis. 2021 Jul 05;: - PubMed
  23. BMJ. 2021 Mar 29;372:n71 - PubMed
  24. Nat Commun. 2021 Aug 26;12(1):5135 - PubMed
  25. NPJ Vaccines. 2021 Mar 25;6(1):44 - PubMed
  26. Science. 2020 Aug 7;369(6504):650-655 - PubMed
  27. Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149 - PubMed
  28. Nat Commun. 2021 Aug 17;12(1):5061 - PubMed
  29. Nature. 2020 Aug;584(7821):450-456 - PubMed
  30. J Clin Invest. 2021 Jun 15;131(12): - PubMed
  31. Nat Rev Microbiol. 2009 Mar;7(3):226-36 - PubMed
  32. RNA Biol. 2011 Mar-Apr;8(2):270-9 - PubMed
  33. Science. 2021 Apr 30;: - PubMed
  34. Science. 2021 Mar 12;371(6534):1152-1153 - PubMed
  35. Cell Host Microbe. 2021 May 12;29(5):819-833.e7 - PubMed
  36. Nature. 2021 Aug;596(7871):273-275 - PubMed
  37. Vaccines (Basel). 2021 May 18;9(5): - PubMed
  38. Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3 - PubMed
  39. Infect Control Hosp Epidemiol. 2021 May 03;:1-2 - PubMed
  40. Nat Commun. 2021 Jun 28;12(1):3991 - PubMed
  41. Nat Med. 2021 Apr;27(4):620-621 - PubMed
  42. Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3 - PubMed
  43. Nature. 2021 Feb;590(7847):630-634 - PubMed
  44. N Engl J Med. 2021 May 13;384(19):1866-1868 - PubMed
  45. Nat Med. 2021 May;27(5):917-924 - PubMed
  46. Science. 2012 Jul 13;337(6091):183-6 - PubMed
  47. Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5 - PubMed
  48. Cell Host Microbe. 2021 May 12;29(5):747-751.e4 - PubMed
  49. Cell Rep. 2021 Jul 20;36(3):109415 - PubMed
  50. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  51. Nature. 2021 Apr;592(7855):616-622 - PubMed
  52. J Evid Based Dent Pract. 2012 Dec;12(4):182-9 - PubMed
  53. Cell. 2021 Apr 29;184(9):2348-2361.e6 - PubMed
  54. Viruses. 2021 Jun 23;13(7): - PubMed
  55. Expert Rev Vaccines. 2021 Apr;20(4):365-373 - PubMed
  56. Cell. 2021 Apr 15;184(8):2201-2211.e7 - PubMed
  57. mBio. 2021 Aug 31;12(4):e0138621 - PubMed
  58. Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9 - PubMed
  59. Science. 2021 Aug 12;: - PubMed
  60. Sci Immunol. 2021 May 25;6(59): - PubMed
  61. Cell. 2021 Aug 5;184(16):4220-4236.e13 - PubMed
  62. EBioMedicine. 2021 Aug;70:103524 - PubMed
  63. N Engl J Med. 2021 Apr 8;384(14):1372-1374 - PubMed
  64. Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4 - PubMed
  65. mBio. 2021 Jun 29;12(3):e0069621 - PubMed
  66. Clin Infect Dis. 2021 May 29;: - PubMed
  67. JAMA. 2021 Apr 6;325(13):1251-1252 - PubMed
  68. J Clin Invest. 2021 May 17;131(10): - PubMed
  69. N Engl J Med. 2021 Jul 29;385(5):472-474 - PubMed
  70. Rev Med Virol. 2021 Mar 16;: - PubMed
  71. Hum Vaccin Immunother. 2021 Sep 2;17(9):2959-2961 - PubMed
  72. Emerg Microbes Infect. 2021 Dec;10(1):1241-1243 - PubMed
  73. N Engl J Med. 2021 May 20;384(20):1959-1961 - PubMed
  74. Nat Med. 2021 Apr;27(4):717-726 - PubMed
  75. Viruses. 2021 Jun 12;13(6): - PubMed
  76. Cell Rep. 2021 Mar 23;34(12):108890 - PubMed
  77. N Engl J Med. 2021 Mar 17;384(15):1468-1470 - PubMed
  78. Nature. 2020 Dec;588(7839):682-687 - PubMed
  79. Rev Med Virol. 2021 Jul 19;:e2277 - PubMed
  80. J Biol Chem. 2021 Jan-Jun;296:100536 - PubMed
  81. Nat Commun. 2020 Sep 17;11(1):4704 - PubMed
  82. Cell. 2020 Nov 12;183(4):1024-1042.e21 - PubMed
  83. Science. 2021 Mar 25;: - PubMed
  84. Sci Immunol. 2021 Apr 15;6(58): - PubMed
  85. Nature. 2021 May;593(7857):136-141 - PubMed
  86. Lancet. 2021 Apr 3;397(10281):1263-1264 - PubMed
  87. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  88. Allergy. 2021 Sep;76(9):2895-2998 - PubMed
  89. Nature. 2021 May;593(7857):130-135 - PubMed
  90. Nat Commun. 2021 May 25;12(1):3109 - PubMed
  91. JAMA. 2021 May 11;325(18):1896-1898 - PubMed
  92. Lancet Respir Med. 2021 Apr;9(4):333-335 - PubMed
  93. Biosaf Health. 2020 Dec;2(4):226-231 - PubMed

Publication Types

Grant support